Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 2Respiratory Distress Syndrome 1Psoriasis 1Pneumonia 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Diabetes Mellitus, Type 1 1Cytokine Release Syndrome 1Bronchiolitis Obliterans 1Adenocarcinoma 1

Interventions

otelixizumab 1fludarabine phosphate 1fludarabine 1Metoprolol 1Interleukin 1 Receptor Antagonist Protein 1Infliximab 1Etanercept 1Cyclophosphamide 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Cytokine Release Syndrome × Etanercept × Clear all
NCT04082910 2022-04-13

Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

Chinese PLA General Hospital

Phase 1/2 Unknown
30 enrolled
Other hematologic neoplasm

Cytokine Release Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡